SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with robust upward momentum and high trading volume, driven significantly by record inflows into its spot ETFs and institutional accumulation. The community is expressing widespread bullish sentiment, anticipating a supply shock and further gains as XRP tests key resistance levels and shows signs of decoupling from broader market trends. Many are eagerly discussing upcoming regulatory clarity as a potential catalyst for continued price appreciation.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending with the launch of its Ryzen AI Embedded Processors for automotive and industrial AI, and intense anticipation for CEO Lisa Su's upcoming keynote at CES. The community is actively discussing potential new AI product revelations like "Helios" and "MI500," asserting AMD's competitive edge against rivals in the burgeoning AI market and eyeing its significant long-term growth potential.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is generating buzz as the community sharply divides over its perceived underperformance against other digital assets. Bulls, however, point to anticipated catalysts like LitVM and Drivechains, alongside strong technical indicators and a looming supply shock, as reasons for an impending significant price move.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending strongly, fueled by market re-rating and community speculation around unexpectedly prolonged patient survival in its pivotal GPS immunotherapy trial for Acute Myeloid Leukemia. This extended trial duration is widely interpreted as a strong signal of the drug's efficacy and transformative potential, driving expectations for a substantial revaluation or a potential buyout, amplified by high trading volume and significant short squeeze speculation.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is gaining significant attention as it unveils its new Core Ultra Series 3 processors, codenamed Panther Lake, at CES, driving excitement for its potential comeback in the semiconductor industry. The community is actively discussing the chips' advancements in AI integration, robotics, and battery life, viewing them as a pivotal moment for Intel to regain market share. Amidst speculation about future foundry success and strategic partnerships, many believe these innovations could challenge competitors and fuel substantial growth.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending, fueled by its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics as a foundational "meme reset." This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid community debate over recent executive share sales, sparking discussion on insider confidence. The market is also reacting to Novo Nordisk's aggressive oral GLP-1 launch, intensifying competitive landscape discussions as investors await potential strategic news or an FDA update on VKTX's oral program at the upcoming J.P. Morgan Healthcare Conference. Despite these factors, many remain bullish on VK2735's potential best-in-class efficacy and tolerability in the expanding obesity market.

"What's Updog?" is a Community Led token.

UpDog

UPDOG is buzzing as its community rallies around the "Whats UpDog?" meme, positioning it as a retail-driven asset built on Solana. Enthusiasts are actively encouraging new holders to join, emphasizing the long-term commitment with their "The Dog Stays Up" mantra.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is a top trending stock following its CES keynote, where CEO Jensen Huang announced the "Vera Rubin" AI platform is in full production and unveiled "Alpamayo" for advanced autonomous driving. The community is buzzing about these innovations solidifying NVIDIA's leadership in the AI and robotics space, though some frustration is surfacing over the stock's price movements despite the positive news.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its dedicated community, "The Flock," celebrates a significant milestone, highlighting the project's blend of meme culture with real-world assets through its CockyWings food truck business and the recently launched MemesHub.io platform. Community discussions emphasize the multiple revenue streams and liquid staking "Arena" that provide passive gains, positioning it as a "MemeFi" innovator on the Cardano blockchain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Here's What Happened

Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Should You Sell...

Penny Stocks To Keep An Eye On - December 3rd

iRobot, Richtech Robotics, Bitfarms, Virax Biolabs Group, Nauticus Robotics, Incannex Healthcare, and Fusion Fuel Green are the seven Penny stocks to watch today, according to MarketBeat's stock...

<ul class="summary-bullets"><li>FDA Fast Track status followed strong Phase 2 efficacy and safety results for IHL-42X.</li><li>The designation provides benefits including a rolling review and closer FDA engagement.</li><li>Stocktwits users highlighted the scale of OSA unmet need and long-term optimism.</li></ul>Incannex Healthcare shares rose nearly 15% on Wednesday after the company said the U.S. Food and Drug Administration (FDA) granted Fast Track designation to IHL-42X, its oral fixed-dose combination candidate for obstructive sleep apnea.<h2 class="st-heading-2">FDA Fast Track Status</h2>Incannex said the designation was supported by results from three completed clinical trials, including its Phase 2 RePOSA study, which showed statistically significant reductions in Apnea-Hypopnea Index with individual reductions of up to 83%, along with favorable patient-reported outcomes and an “excellent safety profile.”The company said the Fast Track status allows more frequent interactions with the FDA, eligibility for rolling review of a future New Drug Application, and potential access to Accelerated Approval and Priority Review if criteria are met.Incannex said it expects detailed written feedback from the FDA on its Phase 2 data package and development strategy and will provide updates once it has reviewed the agency’s guidance.<h2 class="st-heading-2">Generalized Anxiety Disorder Data Adds Momentum</h2>In August, the company reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">positive mid-stage trial results</a> for PSX-001 in generalized anxiety disorder. The study showed statistically significant improvements across all key endpoints, including a strong reduction on the Hamilton Anxiety Rating Scale among 73 participants.<h2 class="st-heading-2">Stocktwits Traders Cheer Fast Track Status</h2>On Stocktwits, retail sentiment for Incannex was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:971/140;" src="https://news.stocktwits-cdn.com/ixhl_ss_png_fd98f44272.webp" alt="ixhl ss.png" width="971" height="140"><figcaption>IXHL sentiment and message volume as of December 3| Source: Stocktwits</figcaption></figure>One user said, “this is incredible news. Fast tracked serves unmet medical needs, meaning this is the only pill in existence for a disease that affect nearly a billion people.”<stembedurl>https://stocktwits.com/user0987134/message/638044052</stembedurl>Another bullish user called the stock a “long hold” and expects further positive developments.<stembedurl>https://stocktwits.com/Rusty26/message/638043151</stembedurl><a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare’s stock</a> has declined 79% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Incannex Healthcare Stock Soars 15% After FDA Fast Tracks Obstructive Sleep Apnea Drug

Incannex’s Fast Track designation for IHL-42X follows strong Phase 2 data and grants the program expanded FDA access and review advantages.

Equity

What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock

Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Incannex Healthcare (NASDAQ:IXHL) Trading Up 1.1% - Still a Buy?

Incannex Healthcare (NASDAQ:IXHL) Shares Up 1.1% - Time to Buy...

Incannex Healthcare Inc. (IXHL) has experienced a 234% increase in retail chatter on Stocktwits over the past seven days, while message volumes have risen 193% over the past 30 days on the platform. Shares of the company drew investor attention on Wednesday morning as it declined nearly 10% at the opening bell.Incannex is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:574/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_9_16_43_AM_png_8958508111.webp" alt="IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="66"><figcaption>IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">announced </a>positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The company stated that the trial results confirm statistically significant and clinically meaningful improvements across all key endpoints assessed, including the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group.Of patients receiving treatment, 27% achieved complete disease remission, which is five times higher than the placebo rate, the company said. Additionally, the firm is exploring strategic partnerships to accelerate development and broaden global access to PSX-001.The company’s other two clinical-stage product candidates, IHL-42X and IHL-675A, are in different stages of development. While IHL-42X has completed a mid-stage clinical trial in obstructive sleep apnoea, IHL-675A is currently in a mid-stage clinical development program for the treatment of inflammatory conditions such as Arthritis.Incannex also <a href="https://stocktwits.com/news-articles/markets/equity/incannex-stock-soars-after-board-authorizes-20-million-share-repurchase-program/chsZIp3RdK2">authorized</a> a $20 million share repurchase program in August. CEO Joel Latham had stated that the program reflects the company’s confidence in the strength of its pipelines and the opportunities ahead. “We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs,” he said.A Stocktwits user, meanwhile, expressed hopes for a partnership or buyout announcement on the company’s next earnings announcement.<stembedurl>https://stocktwits.com/IKEGAI/message/629801176</stembedurl>Shares of the company slumped 71% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.

Incannex Healthcare Inc. (IXHL) on Tuesday announced positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The stock shot up nearly 15% in Tuesday’s pre-market session.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-reports-positive-results-phase-2-clinical-trial-psx-001">said</a> that the results from the trial confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, including on the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group. This difference was statistically significant and sustained across the 11-week follow-up period, the company said.Of patients receiving treatment, 27% achieved full disease remission, five times higher than placebo. Quality of life also improved by an average of 10.6 points on the Personal Wellbeing Index in the PSX-001 group versus 2.7 points for placebo. “Psi-GAD demonstrated a reduction in anxiety, improved mood, enhanced quality of life, and better day-to-day functioning. Importantly, the treatment effect was durable and observed across 11 weeks,” said Lou Barbato, Chief Medical Officer of Incannex.The company is now preparing to initiate a multi-jurisdiction mid-stage clinical trial. Incannex is also exploring strategic partnerships to accelerate development and broaden global access to PSX-001.Treatment with Psi-GAD was well tolerated across the study population, the company said. The majority of treatment-emergent adverse events (TEAEs) were transient, mild to moderate in nature, and consistent with the expected pharmacological effects of Psilocybin, the company said. It added that there were no signs of concerns often cited with psychedelic treatments, such as increased suicidality, psychosis, or prolonged psychological distress. However, one subject withdrew from the trial, Incannex said.&nbsp;IXHL stock is down by 65% this year and by 61% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-oral-drug-delivers-significant-weight-loss-in-late-stage-study/chsHtgtRdj7">Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Is Incannex Healthcare Stock Surging Today? 

The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.

Incannex Healthcare Inc. (IXHL) announced on Friday that its board of directors has authorized a share repurchase program for up to $20 million of the company’s outstanding shares of common stockShares of the company were up 23% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:573/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_11_04_37_AM_png_83c7c67ea2.webp" alt="IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="573" height="60"><figcaption>IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes that the stock will trade over $1 soon.<stembedurl>https://stocktwits.com/Uppy/message/626218079</stembedurl>The company said that it may repurchase shares of common stock through open market purchases, privately negotiated transactions, accelerated share repurchase arrangements, or other methods. The timing and amount of any repurchases will depend on market conditions, available capital resources, among other factors, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-healthcare-authorizes-20-million-share-repurchase">added</a>.CEO Joel Latham said that the firm believes the current market valuation does not accurately reflect the significant progress it has made across its clinical programs. “This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders,” he added.Incannex has three clinical-stage product candidates. Its lead candidate, IHL-42X, an oral fixed-dose combination of Dronabinol and Acetazolamide, is designed for the treatment of obstructive sleep apnea. The other programs are in development for rheumatoid arthritis and generalized anxiety disorder.In July, the company said that it is well-positioned to advance its portfolio of drug candidates through the next stages of development with a cash balance of about $50 million.IXHL stock is down by 73% this year and by 68% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/macquarie-downgrades-li-auto-on-rising-competition-in-chinese-market/chsZ3xRRdKb">This Stock Just Got Downgraded By Macquarie On Rising Competition In Chinese Market – Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

The company’s CEO said that the current market valuation does not accurately reflect the significant progress the firm has made across its clinical programs.

Shares of Incannex Healthcare Inc. hit their highest levels in nearly two months on Wednesday after the company released updates about its lead candidate, IHL-42X, a once-daily oral treatment for obstructive sleep apnea (OSA).The company announced completion of patient dosing for the Phase 2 portion of the RePOSA Phase 2/3 trial on May 8 and expects to finish final follow-up assessments by May 17.&nbsp;Shares of Incannex surged 720% on May 14 to close at $0.70, with the stock rising another 24% to $0.87 in after-hours trading.The program's pharmacokinetic and safety profiles, and clinical knowledge will help progress upcoming development stages and regulatory discussions with the FDA.The FDA end-of-Phase II meeting will formulate regulatory approaches for a new drug application.The company started its Phase 3 preparations, which will enroll 440 patients across multiple U.S. trial sites. U.S. investigators and trial participants drove the decision to concentrate geographically.IHL-42X treats intermittent hypoxia, defined by repeated blood oxygen level decreases, and hypercapnia, which involves carbon dioxide accumulation in the blood from inadequate airflow during sleep.Patients receive a dual therapy of dronabinol and acetazolamide to achieve combined effects that lessen disease severity.The Australian Phase 2 trials revealed that the lowest dose achieved a 51% reduction in the Apnea-Hypopnea Index (AHI) on average.&nbsp;Subsequent studies reported progress in measuring hypoxic burden (HB), which shows a stronger link to cardiovascular outcomes compared to AHI measurements.The company pointed out that IHL-42X may be used as a broader treatment option than weight loss therapies because data reveals that 67% of OSA patients are not obese.&nbsp;It also announced initiation of early commercial engagement initiatives, which demonstrate increasing attention from prospective partners.&nbsp;Incannex has advanced multiple late-stage drug candidates, including IHL-675A targeting inflammatory conditions and PSX-001 for generalized anxiety disorder.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested the sharp move in Incannex was part of what they described as a broader wave of "penny bio pharma mania" unfolding in the market.<stembedurl>https://stocktwits.com/StockFlips/message/614689194</stembedurl>Meanwhile, another user expressed regret over missing the rally while driving and hoped the stock would climb again the next day.<stembedurl>https://stocktwits.com/Moodymoney/message/614690960</stembedurl>The stock has declined 65.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Surges 720% On Sleep Apnea Trial Progress: ‘Penny Bio Pharma Mania’ Lifts Retail Sentiment

The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR